echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Clinical approval of recombinant human mouse chimeric anti-CD20 monoclonal antibody injection

    Clinical approval of recombinant human mouse chimeric anti-CD20 monoclonal antibody injection

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the website of the State Food and drug administration, the approval status of the recombinant human mouse chimeric anti-CD20 monoclonal antibody injection (cxsl1100072) of Haizheng Pharmaceutical Co., Ltd

    has changed to "in approval" since January 14, and the review conclusion is "clinical approval", indicating that the clinical application of the drug has been approved

    The drug is a generic of rituxan, a blockbuster product of Roche's monoclonal antibody

    The main treatment is lymphoma and rheumatoid arthritis

    This product will lay a good foundation for the continuous improvement of the company's subsequent business performance

    Rituxan is the first monoclonal antibody approved for clinical treatment of non Hodgkin's lymphoma (NHL) in the world

    According to the statistics of evaluatepharma, the global pharmaceutical market prediction agency, the global sales of rituxan in 2010-2012 were US $5.034 billion, US $6.14 billion and US $7.143 billion respectively

    At present, there are no domestic enterprises to produce the product, and only 5-6 domestic enterprises apply for the clinical application of the product

    Haizheng pharmaceutical is committed to the research and development of multiple monoclonal antibody drugs, among which ambrano, the first monoclonal antibody drug, is expected to be approved for market in 2014

    The approved clinical recombinant human mouse chimeric anti-CD20 monoclonal antibody injection will contribute to the monoclonal antibody industry of Haizheng pharmaceutical

    At the same time, Haizheng Pharmaceutical Co., Ltd

    has applied for the clinical application of adalimumab, a heavy drug, in November 2013

    With high barriers to entry and significant clinical treatment effect, the McAb drug industry has a very broad market prospect, and it is easy to produce heavy bomb products.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.